<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202643</url>
  </required_header>
  <id_info>
    <org_study_id>09012010-01</org_study_id>
    <nct_id>NCT01202643</nct_id>
  </id_info>
  <brief_title>Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF</brief_title>
  <official_title>G-CSF and Endometrial Growth, Embryo Implantation and Pregnancy Following FET or Donor ET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Human Reproduction</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Reproductive Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Human Reproduction</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of G-CSF on endometrial thickness in
      women who have failed reaching minimal endometrial thickness by standard treatments, to
      assess how many reach embryo transfer and what implantation and pregnancy rates are in
      comparison to control patients. The study will be conducted in women undergoing transfer of
      previously cryopreserved embryos or undergoing transfer of embryos from donor eggs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To investigate the effect of treatment with CSF : A placebo controlled double
      blinded crossover study.

      Design: Crossover Randomized Control Trial

      Setting: Academically affiliated private infertility centers

      Subjects: Female IVF patients of all ages who are willing to be randomized to treatment and,
      in either IVF treatment, frozen embryo cycles (FET) or donor IVF cycles (D-IVF), 5 days
      before ET, have inadequate endometrial thickness.

      Interventions: Subjects receive transvaginally, utilizing an insemination catheter, 2 slow
      intrauterine lavages with CSF-1 (Neupogen or generic, 300ug in 1 ml) 5 and 3 days,
      respectively, before embryo transfer and controls receive 1 ml of saline instead. Patients
      who do not become pregnant will after one month washout times continue treatment in the
      opposite study arm if they so choose and if they have remaining embryos.

      Main Outcome Measures: Number of patients reaching embryo transfer with adequate endometrial
      thickness of at least 7mm.

      Second Outcome Measures: Implantation and pregnancy rates..

      Statistical and Power considerations: This is a Randomized Controlled Trial (RCT) with two
      study arms and panned crossover. Patients will be randomly assigned to Study group A or B
      according to a computer generated randomization table with 50:50 distributions. The study
      will test the null hypothesis that there is no difference in the transfer rates between the
      two groups. Transfer is only possible if the endometrial thickness reaches 7 mm or more.
      Order of treatment ab v ba will be added to the models as a separate factor and each phase
      will be analyzed as separate treatment strata.

      The investigators are planning a study of independent cases and controls with 1 control per
      case. Prior data indicate that the transfer rate among controls is &lt; 1%. If the true transfer
      rate for experimental subjects is 25%, the investigators will need to study 38 experimental
      subjects and 38 control subjects to be able to reject the null hypothesis that the transfer
      rates for experimental and control subjects are equal with probability (power) 0.8. The Type
      I error probability associated with this test of this null hypothesis is 0.05. We will use a
      continuity-corrected chi-squared statistic or Fisher's exact test to evaluate this null
      hypothesis.

      There will be a planned interim analysis after 20 participants have completed the trial and
      if significant effects are observed the trial may be terminated at that time. The power to
      detect a difference in this interim analysis is only 42.6%.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial Thickness</measure>
    <time_frame>Day of embryo transfer</time_frame>
    <description>Thickness of the endometrium on the day of embryo transfer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation Rate</measure>
    <time_frame>28 days after embryo transfer</time_frame>
    <description>Number of gestational sacs per number of embryos transferred in each treatment group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>One infusion of G-CSF 300 units administered by intrauterine infusion</description>
    <arm_group_label>G-CSF</arm_group_label>
    <other_name>NEUPOGEN (Filgrastim)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>One intrauterine saline infusions of 1 cc</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Normal Saline (Salt water)</other_name>
    <other_name>0.91% w/v of NaCl, about 300 mOsm/L</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's preparing for invitro fertilization and embryo transfer with endometrial
             growth of less than 7 mm, unresponsive to standard treatment

        Exclusion Criteria:

          -  Sickle Cell disease

          -  Renal insufficiency

          -  Upper respiratory infection or Pneumonia

          -  Chronic Neutropenia

          -  Known Past or present malignancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Barad, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Gleicher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Reproduction</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>May 18, 2014</results_first_submitted>
  <results_first_submitted_qc>November 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2014</results_first_posted>
  <last_update_submitted>November 25, 2014</last_update_submitted>
  <last_update_submitted_qc>November 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Human Reproduction</investigator_affiliation>
    <investigator_full_name>David H. Barad</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Thin Endometrium</keyword>
  <keyword>Asherman's Syndrome</keyword>
  <keyword>Endometrial Scarring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients presenting for embryos transfer between October 3, 2010, and January 1, 2013, were offered participation in the trial. A total of 419 eligible patients were offered participation: Only 12 patients consented to participate in this study,(129 addtional patient participated in the NCT01202656 study) and 278 declined.</recruitment_details>
      <pre_assignment_details>The principal reasons for refusal to participate were ‘‘lack of interest’’ and technical difficulties in presenting in timely fashion for the treatment to the center. Women with renal disease, sickle cell disease, or a history of malignancy were considered ineligible. No consenting patient was excluded from participation for medical reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-CSF Then Saline</title>
          <description>G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation then Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
        </group>
        <group group_id="P2">
          <title>Saline Then G-CSF</title>
          <description>Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation then G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1">On patient became pregnant following Period 1, Only one non-pregnant chose to cycle again</participants>
                <participants group_id="P2" count="2">Three patients became pregnant after Period 1, 1 patient chose not to cycle again</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The transfer rate among controls should be &lt; 1%. If the true transfer rate for experimental subjects is 25%, we will need to study 38 experimental subjects and 38 control subjects to be able to reject the null hypothesis that the transfer rates for experimental and control subjects are equal with probability (power) 0.8.</population>
      <group_list>
        <group group_id="B1">
          <title>G-CSF Then Saline</title>
          <description>G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation then Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
        </group>
        <group group_id="B2">
          <title>Saline Then G-CSF</title>
          <description>Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation then G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.79" spread="5.13"/>
                    <measurement group_id="B2" value="39.38" spread="6.03"/>
                    <measurement group_id="B3" value="39.59" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FSH</title>
          <description>Day 3 Follicle Stimulating Hormone as a measure of baseline ovarian reserve</description>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.64" spread="3.92"/>
                    <measurement group_id="B2" value="8.27" spread="4.01"/>
                    <measurement group_id="B3" value="8.46" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Endometrial Thickness</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="0.22"/>
                    <measurement group_id="B2" value="6.2" spread="0.69"/>
                    <measurement group_id="B3" value="5.8" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endometrial Thickness</title>
        <description>Thickness of the endometrium on the day of embryo transfer</description>
        <time_frame>Day of embryo transfer</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G-CSF</title>
            <description>G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Thickness</title>
          <description>Thickness of the endometrium on the day of embryo transfer</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="3.1"/>
                    <measurement group_id="O2" value="7.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implantation Rate</title>
        <description>Number of gestational sacs per number of embryos transferred in each treatment group</description>
        <time_frame>28 days after embryo transfer</time_frame>
        <population>Presuming an implantation rate of 10% and anticipating a 10% increase to 20% with treatment, about 200 embryos transferred in each study arm would be needed for 80% power and alpha of 0.05.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF</title>
            <description>G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
          </group>
        </group_list>
        <measure>
          <title>Implantation Rate</title>
          <description>Number of gestational sacs per number of embryos transferred in each treatment group</description>
          <population>Presuming an implantation rate of 10% and anticipating a 10% increase to 20% with treatment, about 200 embryos transferred in each study arm would be needed for 80% power and alpha of 0.05.</population>
          <units>Gestational sacs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>embryos transferred</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Study was closed due to insufficient recruitment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>G-CSF</title>
          <description>G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Barad</name_or_title>
      <organization>Center for Human Reproduction</organization>
      <phone>212 994-4400</phone>
      <email>dbarad@theCHR.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

